Statins, as cholesterol-lowering drugs, are one of the treatments proposed for fatty liver disease. But Liver toxicity is a well recognized adverse effect of treatment with statins. However pre-marketing studies have suggested that rosuvastatin may have a lesser potential to cause liver toxicity as compared with other statins. This study was designed to evaluate the effect of Rosuvastatin on liver enzymes in Patients with Non-Alcoholic Steatohepatitis (NASH).

This study was a double-blind, placebo-controlled, randomized clinical trial. transient elastography (FibroScan) was used to diagnose disease in patients with increased liver enzymes and without other hepatic diseases. A total of 44 participants (Age ≥ 20 years) with NASH were randomly allocated into two groups to receive either rosuvastatin tablet (10 mg daily) or placebo for 6 months. At baseline and at the end of the intervention, serum ALT, and AST were measured in fasting state.

Before the treatment there was no significant difference between two groups with respect to average age, BMI and gender, AST and ALT. After the intervention, a reduction was observed in average amount of ALT and AST in both groups , but it was no significant (P > 0.05). At the end of the study, there was no significant difference in mean serum level of enzymes between the two groups

The use of rosuvastatin (10 mg per day) for 6 months was safe in patients and did not effect on liver enzymes.